Experiences with
Fludarabine819 public posts
CLL survival times ARE improving, thanks to BTK and BCL-2 inhibitors
Those older chemoimmunotherapy treatments, typically Bendamustine + Rituximab (BR) or Fludarabine + Cyclophosphamide + Rituximab (FCR), selected for tougher to treat sub-clones, which they cause through inducing DNA damage that will hopefully trigger apoptosis [u]if[/u] the TP53 gene isn't mutated or
Median PFS for FCR treated CLL patients with IGHV-M was 14.6 years vs 4.2 years for patients with IGHV-UM. V+O and I+R look to be superior
An update of the long-term follow-up results from the original 300-patient FCR (fludarabine, cyclophosphamide, and rituximab) study initiated at MD Anderson in 1999, Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up, reports ~47% of patients with mutated IGHV
Want to take advantage of all our features? Just log in!
or
New Greek consensus statement for the treatment of chronic lymphocytic leukemia
There is now a new consensus statement for the treatment of CLL in Greece. The statement was published on 1 March 2025 and provides treatment recommendations for both first-line and relapsed refractory CLL.
[i]"Abstract. Background: [/i][i]New targeted therapies have revolutionized the treatment